Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Medical Ethics selects Bayer as New Zealand commercial partner for Tri-Solfen®

August 18, 2018

Second country launch for Tri-Solfen®, which is already marketed by Bayer in Australia

An important milestone as the Group continues to expand its international reach and to help minimise suffering associated with wounds

Melbourne, Australia – 26 July 2018 –Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has signed a long-term, exclusive marketing and distribution agreement with Bayer New Zealand for the Group’s lead product, Tri-Solfen®, in New Zealand for use on animals undergoing painful husbandry procedures.

Tri-Solfen® is designed to adhere to wounds to provide rapid onset numbing with prolonged analgesia effects. The innovative spray and stay topical local anaesthetic and antiseptic gel also contains active ingredients designed to minimise bleeding, protect against infection, coat the wound and promote healing.

The Group successfully registered Tri-Solfen®in New Zealand through the Ministry for Primary Industries, which leads and facilitates the management of animal welfare policy and practice in the country. Tri-Solfen®is initially indicated for use on lambs and calves undergoing husbandry procedures. Under the terms of the agreement, Bayer has the right to market the existing and future indications for all animal species (excluding humans).  The Group will be responsible for applying for additional registrations.

Derek Bartlett, Managing Director of Bayer New Zealand, commented: 

“At Bayer, we are firmly committed to improving animal wellbeing, especially alleviating the pain and stress of animal husbandry procedures in farm animals. This product goes a long way to achieving that result. Tri-Solfen®is initially indicated for use on lambs and calves, but we are working with Animal Ethics on approvals for further indications and claims. Innovations such as Tri-Solfen®are important for enhancing animal welfare.  We are currently working towards launching to the New Zealand market in early 2019.”

 Allan Giffard, Managing Director of Medical Ethics, added:

“We are delighted to announce Bayer as our partner in New Zealand to bring our globally recognised technology to this important country. Bayer’s commitment to improving animal welfare make them the ideal partner in New Zealand and, having already demonstrated the success of our relationship in Australia, we are confident we can continue to help minimise suffering associated with wounds in livestock.  Tri-Solfen®is proven to deliver a highly effective, practical and cost-efficient solution to improve animal welfare outcomes and we look forward to continuing to expand the commercial potential of the product.”

Over one billion livestock globally undergo highly invasive painful husbandry procedures annually. Tri-Solfen®is already registered in Australia for sheep and cattle husbandry procedures, where it has been marketed and distributed by Bayer since its launch in 2005. To date, Tri-Solfen®has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries. The global market potential for Tri-Solfen®is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.

Animal Ethics accelerated the expansion of its global registration programmes in 2017 through a commercial partnership with Dechra Pharmaceuticals PLC (Dechra), a FTSE 250 international veterinary pharmaceutical business. As part of the partnership, Dechra became a cornerstone investor in Medical Ethics and, in a separate agreement with Animal Ethics, secured the global licensing rights (excluding Australia and New Zealand) for the Group’s proprietary platform technology in animals. Dechra will support the Group’s strategy to register Tri-Solfen®in major international markets.  As such, the Group submitted a regulatory dossier to the European Medicines Agency in June 2018 to register Tri-Solfen®in Europe for painful husbandry procedures in piglets and dairy calves.

Contacts:

Medical Ethics Pty Ltd  Tel: +61 419 362 286

Allan Giffard, Managing Director

Charles Olsson, Marketing Director

 

FTI Consulting     Tel: +44 20 3727 1000

Brett Pollard, Victoria Foster Mitchell, Abbas Omaar